Breast Cancer Clinical Trial
PEAK PlasmaBladeâ„¢ 4.0 Versus Traditional Electrosurgery in Lumpectomy
Summary
The purpose of this clinical study is to quantify the difference in thermal injury depth at the surgical margin in breast lumpectomy specimens excised with the PlasmaBlade; to subjectively assess histopathologic sample quality metrics; to examine the role that electrosurgical artifact may play in revision lumpectomy procedures; and to compare these endpoints to the standard of care (SOC) technology.
Full Description
Lumpectomy is a surgical procedure performed to remove a localized mass of breast tissue that is suspicious for malignancy. The purpose of lumpectomy is to minimize the amount of tissue removed from the breast to retain normal breast architecture while simultaneously removing all of the suspected cancerous tissue. Typically, a scalpel is used for the skin incision and a traditional electrosurgical device is used to cut away any cancerous tissue.
The PEAK PlasmaBladeâ„¢ uses pulsed radiofrequency (RF) energy and a highly-insulated handpiece design to enable precision cutting and coagulation at the point of application. The PlasmaBlade has received FDA clearance for use in plastic, general, and ear, nose, and throat (ENT) surgery, and has demonstrated a significantly reduced thermal injury profile in incised tissue compared to traditional electrosurgical devices. It is hypothesized that this benefit may improve the pathological analysis of excised breast lumps.
This single site study was granted Institutional Review Board (IRB) approval and conducted between June 2009 and January 2011. Potential subjects were screened against the inclusion and exclusion criteria of the study protocol and were then required to provide informed consent prior to enrollment. Following enrollment, subjects were prospectively randomized to the SOC or PEAK PlasmaBlade study groups and scheduled for lumpectomy.
Eligibility Criteria
Inclusion Criteria:
Age between 18 and 90 years old
Physically healthy, stable weight
Requiring lumpectomy with wire localization for suspected or confirmed malignant breast disease.
Subject must understand the nature of the procedure and provide written informed consent prior to the procedure.
Subject must be willing and able to comply with all follow-up evaluations
Exclusion Criteria:
Age younger than 18 or greater than 90 years old
Infection (local or systemic)
Cognitive impairment or mental illness
Severe cardiopulmonary deficiencies
Unable to follow instructions or complete follow-up
Currently taking any medication known to affect healing
Currently enrolled in another investigational device or drug trial
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Mountain View California, 94040, United States
Mountain View California, 94040, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.